Company Filing History:
Years Active: 2024-2025
Title: Matthew Lakins: Innovator in Antibody Molecule Development
Introduction
Matthew Lakins is a prominent inventor based in Cambridge, GB. He has made significant contributions to the field of biotechnology, particularly in the development of antibody molecules. With a total of 3 patents to his name, Lakins is recognized for his innovative approaches to treating diseases, including cancer.
Latest Patents
Lakins' latest patents include groundbreaking work on antibody molecules that bind PD-L1 and CD137. The first patent describes antibody molecules that can induce agonism of CD137 while binding to PD-L1. This dual functionality is crucial for therapeutic applications, especially in cancer treatment. The second patent focuses on antibody molecules capable of specifically binding to PD-L1 and includes a second antigen-binding site. These advancements highlight Lakins' commitment to developing effective treatments for complex diseases.
Career Highlights
Matthew Lakins is currently associated with Invox Pharma Limited, where he continues to push the boundaries of antibody research. His work has garnered attention in the scientific community, and he is known for his innovative thinking and dedication to improving patient outcomes through biotechnology.
Collaborations
Lakins collaborates with talented professionals in his field, including Jose Munoz-Olaya and Mihriban Tuna. These partnerships enhance the research and development efforts at Invox Pharma Limited, fostering an environment of innovation and discovery.
Conclusion
Matthew Lakins is a key figure in the development of antibody molecules, with a focus on treating diseases such as cancer. His contributions through patents and collaborations underscore his impact on the biotechnology industry.